# Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

> **NCT02642809** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 16 (actual)

## Conditions studied

- Esophageal Cancer
- Cancer of the Esophagus

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Brachytherapy

## Key facts

- **NCT ID:** NCT02642809
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-08
- **Primary completion:** 2020-09-24
- **Final completion:** 2021-08-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02642809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02642809, "Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02642809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*